Nov 3, 8:16 AM ET
Revvity, Inc. reported third quarter 2026 revenue of $729 million and GAAP EPS from continuing operations of $0.56, compared to $699 million and $0.41 a year ago. The company raised its full year 2026 pro forma guidance, forecasting total revenue of approximately $2.86 billion and pro forma adjusted EPS of $5.40-$5.45. Additionally, the company is holding its Investor Day on November 13, 2026.
- Revenue for the third quarter ended October 4, 2026 was $729 million, with pro forma revenue of $710 million representing 7% pro forma organic growth.
- GAAP EPS from continuing operations was $0.56, while adjusted EPS from continuing operations reached $1.38.
- Full year 2026 pro forma guidance forecasts total revenue of approximately $2.86 billion and pro forma adjusted EPS of $5.40-$5.45.
Read the filing on SEC.gov ↗
Aug 4, 6:20 AM ET
Revvity reported second-quarter 2026 revenue of $730 million, up from $720 million a year earlier, and GAAP EPS from continuing operations of $0.48 versus $0.47. The company raised its full-year 2026 guidance and agreed to sell its China Immunodiagnostics business for up to $200 million, a deal it expects to close by the end of 2027.
- Q2 2026 revenue was $730 million, versus $720 million in Q2 2025; adjusted EPS from continuing operations was $1.41, versus $1.18
- Adjusted EPS includes approximately $0.11 from tariff-related refunds, according to the filing
- Full-year 2026 pro forma adjusted EPS guidance is $5.30-$5.40, and pro forma revenue guidance is $2.83-$2.86 billion, excluding China IDX
- China IDX sale for up to $200 million, signed July 31, 2026; expected to close by the end of 2027, subject to conditions and regulatory approvals
Read the filing on SEC.gov ↗
May 5, 6:37 AM ET
Revvity reported first-quarter 2026 revenue of $711 million, up from $665 million a year earlier, and adjusted EPS of $1.06, up from $1.01. The company also said it intends to divest its China Immunodiagnostics business, under a letter of intent for up to $200 million, and updated its full-year 2026 guidance on a pro forma basis.
- Q1 2026 revenue was $711 million vs $665 million a year earlier; GAAP EPS from continuing operations was $0.37 vs $0.35.
- Adjusted operating income was $168 million vs $170 million, and adjusted operating margin was 23.6% vs 25.6%.
- Full-year 2026 pro forma guidance: total revenue of $2.81-$2.84 billion and pro forma adjusted EPS of $5.20-$5.30.
- China Immunodiagnostics was about 6% of 2025 revenue; a letter of intent was signed April 16, 2026, with a definitive agreement expected in Q2 2026 and completion expected in 2027.
Read the filing on SEC.gov ↗
Feb 2, 7:05 AM ET
Revvity reported fourth-quarter 2025 revenue of $772 million, up 6% from a year earlier, and adjusted EPS from continuing operations of $1.70, up from $1.42. For full-year 2025, revenue rose to $2.86 billion and adjusted EPS reached $5.06, though GAAP EPS fell to $2.07 from $2.20. The company also initiated 2026 guidance, which calls for revenue of $2.96 billion to $2.99 billion and adjusted EPS of $5.35 to $5.45.
- Q4 2025 GAAP EPS was $0.87 vs. $0.78 a year earlier; GAAP operating income fell to $112 million from $119 million.
- Diagnostics Q4 revenue rose 10% to $390 million; Life Sciences Q4 revenue rose 2% to $382 million.
- Full-year 2025 revenue was $2,856 million vs. $2,755 million in 2024; GAAP EPS was $2.07 vs. $2.20.
- 2026 guidance: revenue of $2.96 billion to $2.99 billion, organic revenue growth of 2% to 3%, and adjusted EPS of $5.35 to $5.45.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.